Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RotaTeq in infants in Asia and Africa
NCT00362648Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2007
- Primary completion
- Mar 2009
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in rotavirus gastroenteritis comparing RotaTeq with Placebo (2 arms). Primary endpoint: Occurrence of Severe Clinical Rotavirus Disease Caused by Any Rotavirus Serotype. Started Mar 2007; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT00362648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362648.